HPRA Drug Safety Newsletter Edition 78

Download: hpra-drug-safety-newsletter-edition-78.pdf 217 KB

 The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:

Otezla (apremilast) - Important advice regarding suicidal ideation and behaviour

Lenalidomide (Revlimid) - Advice regarding viral reactivation

Levetiracetam 100mg/ml Oral Solution - Global reports of medication errors resulting in the administration of higher than intended doses of levetiracetam

Improved Access to Educational Materials on the HPRA website

Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter

« Back